...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: A lesson on futility analyses from the CETP inhibitors

Hi Bear,

 

I would think that none of those CETP inhibitor trial had anything close to the results of  the pos Hoc analysis RVX 208 had from the ASSURE trial.  With the criteria low HDL and diabetic in the betonmace trial and with now 3 DSMB safety clearances our chances for succeding might very good or better than the CETP inhibitors

Share
New Message
Please login to post a reply